What is already known about this topic?: The effects of concurrent human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection on mortality and patient attrition in those undergoing antiretroviral therapy continue to be a contested area of research.
What is added by this report?: According to the propensity score-matched cohort, individuals with HIV/HCV co-infection exhibit an elevated risk of all-cause mortality [adjusted hazard ratio: 2.048, 95% confidence interval (CI): 1.526-2.749] and attrition (adjusted incidence rate ratio: 1.659, 95% CI: 1.4.8-1.961) compared to their counterparts who are mono-infected with HIV.
What are the implications for public health practice?: The pressing need for tailored testing and follow-up protocols for individuals co-infected with HIV/HCV cannot be overstated.
Keywords: HCV; HIV; antiviral therapy; mortality.
Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023.